VYGR stock forecast
Our latest prediction for Voyager Therapeutics, Inc.'s stock price was made on the March 12, 2019 when the stock price was at 17.51$.
In the short term (2weeks), VYGR's stock price should outperform the market by 2.86%. During that period the price should oscillate between -9.91% and +13.50%.
In the medium term (3months), VYGR's stock price should outperform the market by 1.81%. During that period the price should oscillate between -21.15% and +33.21%.Get email alerts
Create a solid portfolio with VYGR
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
At the moment the company generates 117M USD in revenues.
On its last earning announcement, the company reported a loss of -1.06$ per share.
The book value per share is 2.52$
Three months stock forecastMarch 12, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|